Results 61 to 70 of about 48,966 (221)

Oral Cryptococcosis due to Naganishia diffluens in a Patient With Thalassemia: A Case Report and a Literature Review

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Naganishia diffluens, a rare non‐neoformans cryptococcal species, was identified by PCR sequencing as the causative agent of oral cryptococcosis in a 31‐year‐old Iranian man with β‐thalassemia. This case represents the first documented instance of oral infection by N.
Zahra Yahyazadeh   +13 more
wiley   +1 more source

Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer. [PDF]

open access: yes, 2015
BackgroundCompounded lomustine is used commonly in veterinary patients. However, the potential variability in these formulations is unknown and concern exists that compounded formulations of drugs may differ in potency from Food and Drug Administration ...
Burton, JH   +5 more
core   +2 more sources

Phenotypic and Molecular Characterization of Naganishia uzbekistanensis: Diagnostic Challenges and Antifungal Resistance Profile

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
The graphical abstract summarizes the laboratory characterization of Naganishia uzbekistanensis strain CY11558. The isolate shows distinct colony morphology, globular yeast cells with a fibrillar surface network under scanning electron microscopy, and a weakly positive cryptococcal antigen reaction.
Xin Fan   +7 more
wiley   +1 more source

Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis [PDF]

open access: yes, 2008
Terbinafine, a synthetic allylamine, exerts fungicidal activity against dermatophytes, the causative pathogens of tinea pedis. As proven in numerous clinical trials, tinea pedis can be effectively and safely treated by topical terbinafine.
Korting, Hans Christian   +2 more
core   +1 more source

Health‐Related Quality of Life in Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Qualitative Study

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Epidermal necrolysis (EN), including Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are severe cutaneous drug reactions with high morbidity. However, the quality of life (QoL) impact during acute hospitalization is not well understood.
Jacob McFeeters   +9 more
wiley   +1 more source

∆24-sterol methyltransferase plays an important role in the growth and development of Sporothrix schenckii and Sporothrix brasiliensis

open access: yesFrontiers in Microbiology, 2016
Inhibition of ∆24-sterol methyltransferase (24-SMT) in Sporothrix schenckii sensu stricto and Sporothrix brasiliensis was investigated in vitro. The effects on fungal growth and sterol composition of the 24-SMT inhibitor 22-hydrazone-imidazolin-2-yl-chol-
Luana Pereira Borba-Santos   +9 more
doaj   +1 more source

In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of apergillus terreus Sensu Stricto [PDF]

open access: yes, 2015
The antifungal susceptibilities of 40 clinical and environmental isolates of A. terreus sensu stricto to amphotericin B, terbinafine, itraconazole, and voriconazole were determined in accordance with CLSI document M38-A2.
Cattana, Maria Emilia   +6 more
core   +1 more source

In vitro biofilms and antifungal susceptibility of dermatophyte and non-dermatophyte moulds involved in foot mycosis [PDF]

open access: yes, 2017
Tinea pedis and onychomycosis are among the commonest fungal diseases in the world. Dermatophytes and, less frequently, non-dermatophyte moulds are aetiological agents of foot mycosis and are capable of forming biofilms.
Bougnoux, Marie Élisabeth   +5 more
core   +1 more source

An Unusual Case Report of Iatrogenic Metrorrhagia and Hematochezia Following Itraconazole

open access: yesClinical Dermatology Review
Itraconazole is an effective triazole antimycotic drug that has a desirable pharmacokinetic profile to combat various fungal pathogens. It acts by inhibiting ergosterol biosynthesis in fungal cell membranes.
Yashaswi Rai
doaj   +1 more source

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial

open access: yesCancer Medicine, 2023
Background SHR2554, a novel oral Enhancer of Zeste Homolog 2 inhibitor, shows broad‐spectrum anti‐tumor efficacy in preclinical studies. As SHR2554 is mainly metabolized by CYP3A4, it is helpful to conduct research on the effects of itraconazole, a ...
Kunhong Deng   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy